Bevacizumab, a humanized monoclonal antibody targeted to the VEGFA ligand, was approved for the treatment of recurrent glioblastoma rather than newly diagnosed glioblastomas by the Food and Drug Administration (8). Here, VEGFA is linked to glioblastoma.